Ⅲ期IMpower010随机试验中Ⅱ-ⅢA期非小细胞肺癌全肺切除/双肺叶切除术后辅助阿替利珠单抗的安全性
基于Ⅲ期IMpower010研究,探索Ⅱ-ⅢA期非小细胞肺癌完全切除术后按手术类型(全肺切除/双肺叶切除 vs 肺叶切除/袖状肺叶切除)辅助阿替利珠单抗的安全性。安全性可评估人群871例,阿替利珠单抗组中全肺切除/双肺叶切除占23%(100/433),肺叶切除/袖状肺叶切除占77%(332/433);两组因不良事件停药分别为32%与35%,3/4级不良事件分别为21%与23%。探索性结论支持无论手术类型如何,均可使用辅助阿替利珠单抗。
要点
- 阿替利珠单抗组中全肺切除/双肺叶切除者占23%(100/433),肺叶切除/袖状肺叶切除者占77%(332/433)。
- 全肺切除/双肺叶切除组因不良事件停药32%(n=32),肺叶切除/袖状肺叶切除组35%(n=115)。
- 两组3/4级不良事件分别为21%(n=21)与23%(n=76),因不良事件住院分别为13%(n=13)与17%(n=55)。
核心结论
- 探索性发现支持对完全切除的Ⅱ-ⅢA期PD-L1肿瘤细胞≥1%的非小细胞肺癌患者,在铂类化疗后使用辅助阿替利珠单抗,无论手术类型如何。
研究设计与样本
- Ⅲ期IMpower010随机试验的探索性分析,患者为完全切除的ⅠB-ⅢA期非小细胞肺癌(UICC/AJCC第7版),接受最多4个21天周期的顺铂为基础化疗后1:1随机接受阿替利珠单抗1200 mg每3周(≤16周期或1年)或最佳支持治疗。
- 安全性可评估的随机Ⅱ-ⅢA期人群共871例,按手术类型(全肺切除/双肺叶切除或肺叶切除/袖状肺叶切除)分析不良事件与临床特征。
主要发现
- 阿替利珠单抗组中全肺切除/双肺叶切除100/433(23%),肺叶切除/袖状肺叶切除332/433(77%)。
- 全肺切除/双肺叶切除组与肺叶切除/袖状肺叶切除组因不良事件停药分别为32%(n=32)与35%(n=115)。
- 两组3/4级不良事件分别为21%(n=21)与23%(n=76)。
- 两组因不良事件住院分别为13%(n=13)与17%(n=55);阿替利珠单抗相关不良事件导致住院分别为5%(n=5)与7%(n=23)。
临床怎么用
- 作者认为,探索性结果支持对完全切除的Ⅱ-ⅢA期PD-L1肿瘤细胞≥1%的非小细胞肺癌患者,在铂类化疗后使用辅助阿替利珠单抗,无论手术类型如何。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Adjuvant atezolizumab is a standard of care after chemotherapy in completely resected stage II-IIIA programmed death ligand-1 tumor cell 1% or greater non-small cell lung cancer based on results from the phase III IMpower010 study. We explored the safety and tolerability of adjuvant atezolizumab by surgery type in IMpower010. METHODS: Patients had completely resected stage IB-IIIA non-small cell lung cancer (Union Internationale Contre le Cancer/American Joint Committee on Cancer, 7th Ed), received up to four 21-day cycles of cisplatin-based chemotherapy, and were randomized 1:1 to receive atezolizumab 1200 mg every 3 weeks (≤16 cycles or 1 year) or best supportive care. Adverse events and clinical characteristics were investigated by surgery type (pneumonectomy/bilobectomy or lobectomy/sleeve lobectomy) in the randomized stage II-IIIA population who received 1 or more atezolizumab dose or with 1 or more postbaseline assessment (safety evaluable) for best supportive care. RESULTS: Overall, 871 patients comprised the safety-evaluable randomized stage II-IIIA population. In the atezolizumab arm, 23% (100/433) received pneumonectomy/bilobectomy and 77% (332/433) received lobectomy/sleeve lobectomy. Atezolizumab discontinuation occurred in 32% (n = 32) and 35% (n = 115) of the pneumonectomy/bilobectomy and lobectomy/sleeve lobectomy groups, respectively. Grade 3/4 adverse events were reported in 21% (n = 21) and 23% (n = 76) of patients in the atezolizumab arms in the pneumonectomy/bilobectomy and lobectomy/sleeve lobectomy groups, respectively. In the atezolizumab arms of the surgery groups, 13% (n = 13) and 17% (n = 55) had an adverse event leading to hospitalization. Atezolizumab-related adverse events leading to hospitalization occurred in 5% (n = 5) and 7% (n = 23) of the surgery groups. CONCLUSIONS: These exploratory findings support use of adjuvant atezolizumab after platinum-based chemotherapy in patients with completely resected stage II-IIIA programmed death ligand-1 tumor cell 1% or more non-small cell lung cancer, regardless of surgery type.
引用
- Lee JM, Vallières E, Ding B, et al. Safety of adjuvant atezolizumab after pneumonectomy/bilobectomy in stage II-IIIA non-small cell lung cancer in the randomized phase III IMpower010 trial. J Thorac Cardiovasc Surg. 2023. PMID: 36841745. doi:10.1016/j.jtcvs.2023.01.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。